Creative Planning Buys 4,749 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Creative Planning lifted its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 12.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,151 shares of the biotechnology company’s stock after purchasing an additional 4,749 shares during the period. Creative Planning’s holdings in Ironwood Pharmaceuticals were worth $174,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CWM LLC boosted its position in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 2,345 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Ironwood Pharmaceuticals in the 1st quarter worth $91,000. GAMMA Investing LLC raised its stake in Ironwood Pharmaceuticals by 344.1% during the 2nd quarter. GAMMA Investing LLC now owns 10,526 shares of the biotechnology company’s stock worth $69,000 after buying an additional 8,156 shares during the period. EntryPoint Capital LLC raised its stake in Ironwood Pharmaceuticals by 517.4% during the 1st quarter. EntryPoint Capital LLC now owns 10,589 shares of the biotechnology company’s stock worth $92,000 after buying an additional 8,874 shares during the period. Finally, First Dallas Securities Inc. acquired a new stake in Ironwood Pharmaceuticals during the 2nd quarter worth $73,000.

Ironwood Pharmaceuticals Stock Down 3.6 %

Shares of NASDAQ:IRWD opened at $4.78 on Tuesday. Ironwood Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $15.70. The business has a 50 day moving average of $4.32 and a 200-day moving average of $5.58. The stock has a market cap of $763.56 million, a PE ratio of -159.33 and a beta of 0.47.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The business had revenue of $91.60 million during the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the previous year, the firm posted $0.12 earnings per share. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. Equities research analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Leerink Partners assumed coverage on Ironwood Pharmaceuticals in a research note on Monday, September 9th. They set a “market perform” rating and a $5.00 price objective on the stock. Leerink Partnrs raised Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Wells Fargo & Company dropped their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. Finally, StockNews.com downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $10.40.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.